• OPEN AN ACCOUNT
Indian Indices
Sensex
85,063.34 0.00
( 0.00%)
Global Indices
Nasdaq
49,481.66 483.47
(0.99%)
Dow Jones
6,965.42 42.37
(0.61%)
Hang Seng
52,499.37 666.57
(1.29%)
Nikkei 225
10,156.61 152.04
(1.52%)
Forex
USD-INR
90.21 0.17
(0.19%)
EUR-INR
105.52 0.01
(0.01%)
GBP-INR
121.54 0.38
(0.31%)
JPY-INR
0.58 0.00
(0.26%)

EQUITY - MARKET SCREENER

Catvision Ltd
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
531158
INE660B01011
42.8471102
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
0
10.93
EPS(TTM)
Face Value()
Div & Yield %
0
10
0
 

Strides Pharma slides as US arm receives 4 USFDA observations for New York facility
Dec 26,2025
In an exchange filing, the company said the current Good Manufacturing Practices (cGMP) inspection was conducted by the US Food and Drug Administration (USFDA) at the facility between 17 December and 23 December 2025. At the conclusion of the inspection, the regulator issued a Form 483 containing four observations.

The company clarified that the observations are procedural in nature and are not expected to have any impact on the supply of its commercial products. SPI will submit a comprehensive response to the USFDA within the stipulated timeframe and expressed confidence in addressing all the observations to the regulator’s satisfaction.

Strides Pharma further stated that it will keep the stock exchanges informed of any further developments in this matter. The official announcement was made on 24 December 2025, after market hours.

Strides Pharma Science is a global pharmaceutical company headquartered in Bangalore, India. It develops and manufactures a wide range of niche and technically complex pharmaceutical products.

The company’s consolidated net profit jumped 81.98% to Rs 131.52 crore on a 4.62% increase in revenue from operations to Rs 1,220.83 crore in Q2 Sept 2025 over Q2 Sept 2024.